Table 3. Subgroup analysis of HR in overall survival (OS) by univariate and multivariable analyses.
| Group | Study (N) | Heterogeneity test | HR (95% CI) | P | ||
|---|---|---|---|---|---|---|
| I2(95%CI) | H(95%CI) | P | ||||
| Overall survival(U) | 9 | 75%(51%-87%) | 2.0(1.4–2.8) | <0.001 | 1.878(1.378–2.562) | <0.001 |
| Country | ||||||
| China | 8 | 77%(53%-88%) | 2.1(1.5–2.9) | <0.001 | 1.831 (1.315–2.550) | <0.001 |
| Japan | 1 | - | - | - | - | |
| Sample | ||||||
| ≤200 | 6 | 0%(0%-75%) | 1.0(1.0–2.0) | 0.831 | 2.251(1.806–2.805) | <0.001 |
| >200 | 3 | 83%(49%-94%) | 2.4(1.4–4.3) | 0.002 | 1.352(0.807–2.264) | 0.252 |
| Cancer type | ||||||
| SCC | 2 | 55.7% | 0.160 | 1.724(1.060–2.802) | 0.028 | |
| AC | 1 | - | - | - | - | |
| Year | ||||||
| 2013–2015 | 6 | 80%(57%-91%) | 2.2(1.5–3.3) | <0.001 | 1.736(1.159–2.601) | 0.007 |
| 2009–2012 | 3 | 0.0%(0%-90%) | 1.0(1.0–3.1) | 0.851 | 2.229(1.638–3.034) | <0.001 |
| Overall survival(M) | 9 | 70%(40%-85%) | 2.0(1.3–2.6) | 0.001 | 1.266(0.906–1.768) | 0.167 |
| Region | ||||||
| China | 6 | 71%(31%-87%) | 1.8(1.2–2.8) | 0.005 | 1.168(0.814–1.676) | 0.4 |
| Japan and USA | 3 | 75%(18%-92%) | 2.0(1.1–3.6) | 0.018 | 1.584(0. 643–3.899) | 0.317- |
| Sample | ||||||
| ≤200 | 8 | 74%(47%-87%) | 2.0 (1.4–2.8) | <0.001 | 1.296(0.851–1.975) | 0.225 |
| >200 | 1 | - | - | - | - | |
| Cancer type | - | - | - | - | ||
| SCC | 2 | 58.9% | 0.119 | 1.414(0.883–2.265) | 0.149 | |
| AC | 1 | - | - | - | ||
| Year | ||||||
| 2013–2015 | 7 | 72%(38%-87%) | 1.9(1.3–2.8) | 0.002 | 1.273(0.886–1.830) | 0.191 |
| 2009–2012 | 2 | 81.9% | 0.019 | 1.226(0.352–4.267) | 0.748 | |
U: univariate analysis, M: multivariable analysis, SCC: squamous cell carcinoma, AC: Adenocarcinoma.